Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen

Japanese Journal of Clinical Oncology

Volumn 38, Issue 1, 2008, Pages 36-42

  Tomioka, Susumu ^a   Shimbo, Masashi ^a   Amiya, Yoshiyasu ^a   Nakatsu, Hiroomi ^a   Murakami, Shino ^a   Shimazaki, Jun ^b  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Hormone refractory cancer; Nadir PSA; Prostate cancer; PSA relapse; PSA doubling time

Indexed keywords

BICALUTAMIDE; CHLORMADINONE ACETATE; DEXAMETHASONE; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CODING; PREDICTION; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 39049141662     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym153     Document Type: Article

References (46)

1. Eisenberger MA, Carducci M. Treatment of hormone-refractory prostate- cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA editors. Campbell-Walsh Urology, Vol 3, 9th edn. Philadelphia, PA: Sounders 2007;3101-17.
2. Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death. Int J Urol 2007; 14:123-7.
3. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 1999; 17:3461-7.
4. Oefelein MG, Agarwal PIC, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004;471:1525-8.
5. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7.
6. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapiy-naive androgen independent prostate cancer. Eur Urol 2006;49:666-74.
7. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer analysis of two cancer and leukemia group B studies. Clin Cancer Res 1999;5:831-7.
8. Sylvester RJ, Denis L, de Voogt H, and EORTC. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur Urol 1998;33:134-43.
9. Smaletz O, Scher H, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-82.
10. Halabi S, Vogelzang NJ, On S-S, Kelly WK, Small EJ. Clinical outcomes by age in men with hormone refractory prostate cancer: A pooled analysis of 8 cancer and leukemia group B (CALGB) studies. J Urol 2006;176:81-6.
11. Reynard JM, Peters TJ, Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer - a multivariable analysis of prostate cancer mortality. Br J Urol 1995;75:507-15.
12. Matzkin K Eber P, Todd B, van der Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostate cancer. Cancer 1992;70:2302-9.
13. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-reftactory prostate cancer. J Clin Oncol 1998;16:1835-43.
14. Small EJj Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol 2002;20:3369-75.
15. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004;108:877-81.
16. D'Amico AV, Chen M-H, Cox MC, Dahut W, Figg WD. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology 2005;66:571-6.
17. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002;168:995-1000.
18. Collette, L, de Reijke TM, Schroeder FH, and EORTC. Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003;44:182-9.
19. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2007;25:1596-1605.
20. Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 2007;109:41-7.
21. Kelloff GJ, Coffey DS, Chalmer BA, Dicker AP, Guyton KZ, Nisen PD, et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004;10:3927-33.
22. Teahan SJ, Klotz LH. Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. BJU Int 2006;97:451-5.
23. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006;106:1047-53.
24. Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: Not as easy as 1, 2, 4. J Urol 2006;176:1927-37.
25. Kakehi Y, Kamoto T, Shiraishi T, Kato T, Tobisu K, Akakura K, et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol 2002;41:47-53.
26. Ross PL. Mahmud S, Stephenson AJ, Souhami L, Tanguay S, Aprikian AG. Variations in PSA doubling time in patients with prostate cancer on 'watchful waiting': Value of short-term PSADT determinations. Urology 2004;64:323-8.
27. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006;176:1392-8.
28. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:2244-8.
29. D'Amico AV, Chen M-H, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23:4975-9.
30. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007;25:1765-71.
31. Akimoto S, Masai M, Akakura K, Shimazaki J. Tumor marker doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995;27:207-12.
32. Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 2003;62(Suppl 6B):128-33.
33. Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J Urol 2004;172:141-5.
34. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006;68:565-9.
35. Rozhansky F, Chen M-H, Cox MC, Dahut W, Figg WD, D'Amino AV. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2006;106:63-7.
36. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combinathon with ketocodazole in androgen-independent prostate cancer patients: A phase III Trial (CALGB 9583). J Clin Oncol 2004;22:1025-33.
37. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171:679-83.
38. Kucuk O, Fisher E, Moinpeur CM, Coleman D, Hussain MHA, Sartor AO, et al. Phase II trial of bicaltamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed a southwest oncology group study (SWOC 9235). Urology 2001;58:53-8.
39. Lam JS, Leppert JT, Vemulapalli SN, Slivarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175:27-34.
40. Iversen P, Rasmussen F, Asmussen C, Christensen JJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol 1997; 157:929-34.
41. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, et al. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int 2005;75:43-9.
42. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997;50:401-7.
43. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al. Oral estramustine and oral etoposide for 'hormone-reftactory prostate cancer. Urology 1997;50:754-8.
44. Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, et al. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up. Urol Oncol 2005;23:1-7.
45. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-6.
46. Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T, et al. Possible mechanism of dexamethasone therapy tor prostate cancer: suppression of circulating level of interleukin-6. Prostate 2003;56:106-9.